Gain Therapeutics (GANX) Cash & Equivalents (2020 - 2026)

Gain Therapeutics' Cash & Equivalents history runs 7 years deep, the most recent figure standing at $16.5 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 82.35% year-over-year to $16.5 million; the TTM figure through Mar 2026 stood at $16.5 million (up 82.35% YoY), while the FY2025 annual figure was $20.8 million, up 100.63% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $16.5 million, down from $20.8 million in the prior quarter.
• The five-year high for Cash & Equivalents was $34.3 million in Q1 2022, with the low at $4.3 million in Q3 2023.
• The 5-year median for Cash & Equivalents is $10.6 million (2024), against an average of $12.2 million.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents slumped 82.56% in 2023, then soared 180.87% in 2024.
• Gain Therapeutics' Cash & Equivalents stood at $7.3 million in 2022, then soared by 61.32% to $11.8 million in 2023, then dropped by 11.95% to $10.4 million in 2024, then soared by 100.63% to $20.8 million in 2025, then declined by 20.63% to $16.5 million in 2026.
• Business Quant data shows GANX's Cash & Equivalents at $16.5 million in Q1 2026, $20.8 million in Q4 2025, and $8.8 million in Q3 2025.